Every morning, patients and their families pin hopes on new antibody drugs like lecanemab and donanemab, which modestly slow cognitive decline. Yet these treatments neither reverse the disease nor restore normal brain function. The gap between drugs that seem to work and those that actually stop Alzheimer's has forced researchers to ask a fundamental question: what if we've been aiming at the wrong target all along?
The Multi-Factor Architecture of Alzheimer's Disease
A team led by Professor Yan-Jiang Wang at the Third Military Medical University in China published a review in *Science China Life Sciences* that dissects why Alzheimer's therapy has stalled. The researchers argue that the single-cause approach—focusing almost exclusively on amyloid beta (Aβ) plaques—has failed because the disease itself is far more complex. Alzheimer's, they contend, is the combined result of amyloid beta accumulation, tau protein tangles, genetic risk factors (such as APOE ε4), age-related changes, and systemic health conditions.
Specifically, the team emphasizes that tau hyperphosphorylation—the process that drives neurofibrillary tangle formation and neuronal loss—is at least as important as amyloid beta. Targeting both pathologies simultaneously, they argue, could slow disease progression more effectively than attacking either alone. The review also touches on the potential for one-time treatments using CRISPR/Cas9 gene editing, though this remains at an early conceptual stage.
Why Single-Target Therapies Fell Short
The previous paradigm treated Alzheimer's as an amyloid beta problem, pouring resources into antibody therapies that clear plaques from the brain. Those drugs showed marginal clinical benefit while carrying risks like ARIA (amyloid-related imaging abnormalities). The Wang team now identifies aging itself as the most powerful risk factor—one that single-target drugs cannot address.
Aging brings a cascade of biological changes: mitochondrial dysfunction, accumulation of damaged cells, increased DNA damage, and chronic low-grade inflammation. The review points to senolytic therapies—drugs that selectively eliminate aged, dysfunctional glial cells—as a promising avenue for improving brain health and slowing cognitive decline. Meanwhile, the gut-brain axis and systemic health are gaining attention. Evidence is accumulating that insulin resistance, hypertension, and gut microbiome imbalances can exacerbate Alzheimer's pathology. The researchers note that existing diabetes medications and therapies targeting the gut-brain axis could help mitigate these effects.
What This Means for Patients and Developers
The integrated strategy the team proposes represents a shift from reductionist thinking to what they call "integrated strategies." This includes developing therapies that attack multiple disease pathways at once, adopting advanced experimental models like human iPSC-derived organoids, and using early biomarkers such as plasma pTau217 for precision medicine.
Plasma pTau217 testing is already drawing attention as a tool that can diagnose Alzheimer's more accurately before symptoms appear—potentially years earlier than current methods. The team concludes that "the success of conquering Alzheimer's depends on interdisciplinary collaboration and holistic innovation."
Alzheimer's is no longer a single-target problem. It is a network disease where aging and systemic health intertwine, and the treatments that finally make a difference will likely come from attacking it on multiple fronts at once.
